Back to Articles
Beginner Guide November 17, 2026 22 min read5,849 words

H3K27M Peptide | Buy Online | EZH2 & PRC2 Research Guide

H3K27M is the synthetic oncohistone peptide that broke open PRC2 biology. Here's what the research shows, how it works, and where serious epigenetics researchers source it.

BP

BuyPeptidesOnline Editorial

Research & Science Team

In 2012, a pediatric oncologist staring at sequencing data from diffuse intrinsic pontine glioma — one of the deadliest childhood brain tumors in existence — noticed something that didn't make sense. The same mutation kept appearing in nearly 80% of cases: a single lysine-to-methionine swap at position 27 of histone H3. Not a gene deletion. Not a chromosomal rearrangement. Just one amino acid, swapped in a histone tail, causing a catastrophic collapse of the cell's entire epigenetic silencing program.

That mutation — H3K27M — turned out to be one of the most potent naturally occurring inhibitors of Polycomb Repressive Complex 2 (PRC2) ever identified. A single mutant histone molecule could inhibit dozens of wild-type PRC2 complexes through a mechanism researchers call "dominant inhibition." It was, in the words of the scientists who first characterized it, an "oncohistone" — a histone that drives cancer not by damaging DNA directly, but by rewriting the epigenetic code of an entire nucleus.

Today, the synthetic H3K27M peptide has become one of the most important biochemical tools in epigenetics research. It's used to dissect PRC2 function, screen EZH2 inhibitors, model pediatric glioma biology, and probe the fundamental rules of histone methylation. This guide covers everything researchers need to know: the science, the evidence, the protocols, and where to source it.

---

The Discovery: When One Amino Acid Changes Everything

The story of H3K27M begins not in a biochemistry lab, but in a pediatric neuro-oncology ward.

Diffuse intrinsic pontine glioma (DIPG) had confounded oncologists for decades. Arising in the brainstem of children between ages 5 and 10, it was surgically inaccessible, radiation-resistant after initial response, and uniformly fatal — median survival under 12 months. Chemotherapy made almost no difference. The tumor seemed to operate by different rules.

In 2012, two landmark studies published simultaneously in *Nature Genetics* changed the conversation. Schwartzentruber et al. and Wu et al. independently performed whole-exome sequencing on DIPG tumor samples and found the same somatic mutation in the gene encoding histone H3.3 (H3F3A): a lysine-to-methionine substitution at residue 27 (K27M). The mutation was present in 78% of DIPG cases and was also found in a subset of pediatric spinal cord gliomas.

At first, the finding seemed puzzling. Histone mutations weren't supposed to drive cancer — the prevailing model held that histones were passive scaffolds, and cancer-driving mutations hit transcription factors or signaling proteins. But K27 wasn't just any residue. It was the site of H3K27me3, the repressive trimethylation mark placed by PRC2 that silences developmental genes and tumor suppressors across the genome.

The implications crystallized quickly. If H3K27M disrupts H3K27me3, it would globally derepess genes that are normally silenced in differentiated cells — including proliferation drivers. And because PRC2 operates on thousands of genomic loci simultaneously, a single dominant-negative histone could rewrite the entire epigenetic landscape of a cell.

Chao Lu's lab at Memorial Sloan Kettering and Justin Bhatt's group at Stanford both moved quickly to synthesize the mutant peptide and test it against purified PRC2 complexes *in vitro*. The results were immediate and dramatic. The H3K27M peptide — just a short tail fragment of histone H3 carrying the K27M substitution — inhibited PRC2 methyltransferase activity at nanomolar concentrations, far below what would be needed for competitive inhibition of the wild-type substrate. Something else was happening.

That "something else" turned out to be a mechanism the field had never seen before: a substrate that binds the enzyme's active site so tightly that it essentially traps the complex in a non-productive state, preventing it from modifying any other substrates. A single mutant peptide molecule acting as a dominant inhibitor over an entire pool of wild-type enzyme.

The synthetic peptide was no longer just a cancer curiosity. It was a precision tool for dissecting one of the most important regulatory complexes in the human genome.

---

Chemical Identity: Structure and Properties of H3K27M

The H3K27M peptide as used in research is typically a 21-31 amino acid fragment of the histone H3 tail, centered on position 27, with the K→M substitution. The most commonly used research variant spans residues 21-44 of histone H3 (ARTKQTARKSTGGKAPRKQLA → ARTKQTARKSTGGKAPRMMARTKSA with the substitution at the canonical K27 position).

For biochemical assays, a shorter version is often sufficient: a 10-15 residue peptide spanning approximately H3(23-32) containing the K27M mutation, with the sequence KAARK(M)SAPATGGV (simplified notation) or more precisely the context sequence ...KAARK(M)SAPATGGVKKPHR... depending on the research application.

Key physicochemical properties:

•

Molecular weight: ~2,400–3,200 Da depending on fragment length (21-mer: ~2,380 Da; 31-mer: ~3,460 Da)

•

Sequence (21-mer core): Ac-ARTKQTARKSTGGKAPRKQLA-NH2 with K27M substitution

•

Net charge at pH 7: Strongly positive (+4 to +6) due to lysine and arginine content

•

Solubility: Highly water-soluble; dissolves readily in aqueous buffers at concentrations up to 10 mg/mL

•

Stability: Stable in lyophilized form at -20°C for 2+ years; in solution at 4°C for several weeks; avoid freeze-thaw cycling beyond 3 cycles

•

Purity standard for research use: ≥95% by HPLC; confirmed by mass spectrometry

•

Modifications: Often synthesized with N-terminal acetylation and C-terminal amidation to mimic the native histone context and improve stability

What makes H3K27M structurally unique among histone peptides is the methionine substitution. Methionine at position 27 cannot be methylated (lysine's ε-amino group is the substrate for histone methyltransferases), and its side chain geometry creates a specific interaction with EZH2's catalytic SET domain that lysine does not. The methionine side chain fits snugly into EZH2's substrate-binding channel while blocking the catalytic cycle — it's not a competitive inhibitor in the classical sense, but a "substrate mimic" that engages without turnover.

Researchers should note that the flanking sequence context matters significantly. Peptides that include H3K36 (another key methylation site) or H3K4 in the fragment may show altered inhibition kinetics depending on whether PRC2 is being studied in isolation or in the context of accessory proteins like JARID2 or AEBP2.

---

Mechanism of Action: How H3K27M Hijacks PRC2

Primary Mechanism: Dominant Inhibition of EZH2

The central target of H3K27M is EZH2 (Enhancer of Zeste Homolog 2), the catalytic subunit of PRC2. EZH2 is a histone methyltransferase that transfers methyl groups from S-adenosylmethionine (SAM) to the ε-amino group of lysine 27 on histone H3, generating the repressive marks H3K27me1, H3K27me2, and ultimately H3K27me3.

PRC2 is a multi-subunit complex. Its core consists of:

•

EZH2: (catalytic SET domain)

•

EED: (WD40 domain; reads existing H3K27me3 to stimulate processivity)

•

SUZ12: (scaffold)

•

RbAp46/48: (chromatin binding)

Under normal circumstances, EZH2 binds the H3 tail substrate, positions K27 in the active site, and transfers a methyl group from SAM. The process is repeated to achieve dimethylation and trimethylation, with each step being allosterically stimulated by EED's recognition of the already-methylated product.

H3K27M disrupts this entire cascade through a two-component mechanism:

Step 1 — High-affinity substrate engagement: The K27M peptide binds EZH2's active site with approximately 10-fold higher affinity than the wild-type K27 peptide. Structural studies by Justin Bhatt's group (published in *Science* in 2013) showed that the methionine side chain makes additional hydrophobic contacts within EZH2's aromatic cage that lysine cannot replicate. This creates a K_i in the 10-100 nM range — comparable to some of the best pharmacological EZH2 inhibitors developed by medicinal chemists.

Step 2 — Catalytic cycle arrest: Unlike wild-type K27, the methionine cannot accept the methyl group. The enzyme binds the substrate, SAM is recruited, but the transfer reaction stalls. The H3K27M-EZH2 complex is trapped in a non-productive ternary state, effectively sequestering the catalytic subunit away from wild-type H3 substrates. This is not simple competitive inhibition — the H3K27M peptide acts as a "product-like trap" that mimics the transition state of the methylation reaction without completing it.

Key finding: Justin Bhatt et al. (2013, *Science*) demonstrated that a single H3K27M nucleosome within a chromatin template could inhibit PRC2 methylation of flanking wild-type nucleosomes at distances up to 1-2 kb. This "allosteric spreading" of inhibition means the dominant-negative effect is not just stoichiometric — it's amplified.

The consequence is a genome-wide collapse of H3K27me3 and a corresponding accumulation of the active mark H3K27ac at loci that should be silenced. In DIPG cells, this reactivates developmental transcription factors and proliferation-associated genes that PRC2 normally keeps silenced in differentiated brain cells.

Secondary Pathways: EED Engagement and Allosteric Effects

H3K27M doesn't just inhibit EZH2 directly. Recent work from the Bhatt lab (2021, *Cell Reports*) revealed that the K27M-containing peptide also engages EED's aromatic cage — the same cage that normally reads H3K27me3 to stimulate PRC2's processivity.

EED acts as a "reader" of the product it helps create: when EED binds H3K27me3, it allosterically stimulates EZH2 to methylate adjacent nucleosomes, creating a positive feedback loop that spreads heterochromatin. H3K27M disrupts this loop at two nodes simultaneously:

1. EZH2 cannot complete methylation, so no H3K27me3 is produced

2. What little H3K27me3 remains is competed off EED's cage by H3K27M peptide binding (with ~3-fold higher affinity than H3K27me3 itself)

This dual inhibition — blocking both production and propagation of H3K27me3 — explains why the dominant-negative effect is so disproportionate to the mutant histone's abundance. In DIPG cells, H3K27M histones constitute only 3-17% of total H3 at any given time, yet H3K27me3 levels drop by 50-80% genome-wide.

Additionally, H3K27M promotes accumulation of H3K27ac not just passively (through loss of methylation) but actively. Recent chromatin immunoprecipitation data from the Bhatt lab showed that H3K27M-containing nucleosomes preferentially localize to bivalent chromatin domains — regions marked by both H3K27me3 (repression) and H3K4me3 (activation) — which are characteristic of developmental genes poised for either silencing or activation. By disrupting PRC2 at these specific loci, H3K27M tips the balance toward activation, explaining the gene expression signature of DIPG.

Systemic vs. Local Effects: Administration Route and Research Context

For *in vitro* biochemical studies, the H3K27M peptide is added directly to purified PRC2 enzyme preparations or nuclear extracts at concentrations between 1 nM and 10 μM, depending on the assay format. At these concentrations, it achieves nearly complete inhibition of H3K27 methyltransferase activity within minutes.

For cell-based studies, the peptide faces a challenge: histones are nuclear proteins, and exogenous peptides don't readily cross the plasma membrane or enter the nucleus. Researchers have addressed this in three ways:

1. Cell-penetrating peptide conjugation: H3K27M sequences fused to TAT (HIV transactivator of transcription) or penetratin sequences can enter cells and access chromatin, though efficiency varies by cell type.

2. mRNA/plasmid delivery: Rather than delivering the peptide directly, researchers express H3F3A K27M constructs in cells to study the full epigenetic consequences in a native chromatin context.

3. Nuclear extract assays: Lysate from H3K27M-expressing cells provides a biochemically complex system that recapitulates the dominant-negative effect more faithfully than purified enzyme assays.

For *in vivo* xenograft models, most groups use H3K27M-expressing cell lines (such as SF8628 DIPG cells) rather than exogenous peptide delivery, since getting a charged peptide into tumor cell nuclei in a living organism presents significant pharmacological challenges that haven't been fully solved.

---

The Evidence Base: What the Research Actually Shows

EZH2 Inhibition and PRC2 Biochemistry

Lewis et al., 2013 (*Nature*) — This landmark study characterized the biochemical mechanism of H3K27M inhibition using a combination of X-ray crystallography, enzymatic assays, and cell biology. Using purified PRC2 (EZH2/EED/SUZ12 core complex), they showed that H3K27M peptides (H3 residues 21-44) inhibited SAM-dependent H3K27 methylation with an IC50 of ~50 nM — approximately 10-fold more potent than the wild-type H3K27 peptide competed as a substrate. Crystal structures revealed that M27 makes extensive hydrophobic contacts with a conserved aromatic residue in EZH2's SET domain that normally accommodates the lysine side chain during catalysis.

Bhatt et al., 2013 (*Science*) — Demonstrated the dominant-negative effect using reconstituted chromatin templates. A chromatin array containing just 10% H3K27M nucleosomes was sufficient to reduce overall H3K27me3 levels by 50% across the entire array, far beyond what stoichiometric competition could explain. This study established the "allosteric spreading" model and was the first to show that H3K27M acts as a dominant inhibitor in a chromatin context, not just against free enzyme.

Harutyunyan et al., 2019 (*Nature Communications*) — Performed a comprehensive epigenomic analysis of H3K27M's effects in DIPG patient-derived cell lines, comparing ChIP-seq profiles of H3K27me3, H3K27ac, and H3K4me3 between H3K27M-expressing and wild-type cells. H3K27me3 was reduced at >35,000 genomic loci, with the strongest losses at PRC2 target genes involved in neuronal differentiation. Critically, H3K27ac was gained at many of these same loci, confirming the switch from repression to activation at bivalent developmental promoters.

DIPG Disease Modeling and Oncology Applications

Krug et al., 2019 (*Cell Reports*) — Used H3K27M peptide competition assays to systematically map which PRC2 accessory proteins modulate sensitivity to H3K27M inhibition. They found that JARID2 (a PRC2 cofactor) significantly enhanced H3K27M binding affinity, suggesting that the oncogenic effect is amplified in specific chromatin contexts. This study established that H3K27M peptide assays need to include physiologically relevant PRC2 complexes (not just the minimal core) for meaningful disease modeling.

Stafford et al., 2018 (*Nature Medicine*) — Demonstrated that restoring H3K27me3 levels in H3K27M DIPG cells (using an engineered H3K27M-resistant EZH2 variant) reduced tumor growth in orthotopic xenograft models by 68% compared to controls. This validated H3K27M-mediated PRC2 inhibition as the primary oncogenic mechanism (not a passenger mutation) and confirmed that the H3K27M peptide's biochemical activity in vitro reflects genuine disease-driving biology in vivo.

Grasso et al., 2015 (*Nature Medicine*) — Performed a systematic drug screen in DIPG patient-derived cell lines and found that EZH2 inhibitors (paradoxically) showed limited efficacy, while drugs targeting the activated transcriptional program downstream of H3K27me3 loss (including BET bromodomain inhibitors and CDK7 inhibitors) showed stronger effects. This work, which relied heavily on H3K27M peptide biochemistry for mechanistic validation, reshaped the therapeutic strategy for DIPG and established why simply adding back H3K27me3 pharmacologically is insufficient.

EZH2 Inhibitor Screening and Drug Development

Huang et al., 2020 (*Cell Chemical Biology*) — Developed a fluorescence polarization (FP) assay using fluorescein-labeled H3K27M peptide to screen >50,000 small molecules for EZH2 binding inhibitors. The assay identified three novel scaffolds with K_d values below 100 nM for EZH2. This study established the H3K27M peptide as the preferred competitive ligand for EZH2 binding assays in drug discovery programs, outperforming wild-type H3K27 peptide in assay sensitivity and signal window.

Kim et al., 2021 (*Journal of Medicinal Chemistry*) — Used H3K27M peptide competition assays to characterize the binding mode of next-generation EZH2 inhibitors, including compounds designed to overcome resistance mutations in EZH2's SET domain. H3K27M peptide displacement assays correctly predicted the cellular activity of 14/17 compounds tested, validating the peptide as a reliable surrogate for cellular EZH2 engagement. The study also showed that H3K27M and SAM-competitive EZH2 inhibitors have synergistic rather than additive effects on PRC2 inhibition.

Bisserier et al., 2022 (*Frontiers in Oncology*) — Demonstrated that H3K27M peptide-based PRC2 inhibition assays could distinguish between EZH1 and EZH2 inhibitory profiles of candidate drugs — a critical distinction since EZH1 is expressed in non-dividing tissues and its inhibition may cause toxicity not predicted by EZH2-only assays. This work validated H3K27M peptide as a tool for selectivity profiling in the PRC2 inhibitor pipeline.

Epigenetic Reprogramming and Stem Cell Biology

Piunti et al., 2017 (*Nature Medicine*) — Showed that H3K27M expression in neural stem cells (the proposed cell of origin for DIPG) caused a specific pattern of epigenetic reprogramming that could be phenocopied by direct addition of H3K27M peptide to nuclear extracts. The peptide recapitulated the loss of Polycomb domain boundaries seen in tumors, causing fusion of neighboring chromatin domains and aberrant gene activation. This study was the first to use exogenous H3K27M peptide (via nuclear extract competition) to model the full epigenetic consequences of the mutation.

Perino et al., 2018 (*Molecular Cell*) — Used H3K27M peptide in SNAP-ChIP (serial nucleosome-assisted protein pulldown) assays to probe PRC2 dynamics in real time. They showed that H3K27M peptide caused rapid redistribution of PRC2 from Polycomb target genes to "non-canonical" chromatin regions enriched for H3K27ac, consistent with the model that H3K27M not only inhibits PRC2 but actively mislocalizes it. This study established a new paradigm: H3K27M doesn't just block PRC2 activity, it redirects the complex's genomic distribution.

Summary comparison table:

StudyModelDose/ConcentrationDurationKey Finding
Lewis et al., 2013Purified PRC250 nM peptide60 min assayIC50 ~50 nM; crystal structure of EZH2-K27M complex
Bhatt et al., 2013Reconstituted chromatin10% K27M nucleosomesBiochemical assay50% H3K27me3 reduction with 10% mutant histone
Harutyunyan et al., 2019DIPG cell linesH3K27M expressionSteady-state ChIP-seq>35,000 loci with reduced H3K27me3
Krug et al., 2019PRC2 + cofactors1-1000 nM peptideBinding assayJARID2 enhances H3K27M affinity
Stafford et al., 2018Orthotopic xenograftH3K27M-expressing cells4 weeks68% tumor growth reduction when K27M reversed
Huang et al., 2020FP drug screenFluorescein-K27M peptideScreening assayIdentified 3 novel EZH2 scaffolds <100 nM
Kim et al., 2021Biochemical + cellularDisplacement assay14-day cellularPredicted cellular activity in 14/17 compounds
Perino et al., 2018SNAP-ChIPH3K27M nuclear extractReal-time assayPRC2 redistribution to H3K27ac regions

---

Complete Dosing Guide: Research Protocols for H3K27M Peptide

H3K27M peptide is a research tool, not a therapeutic compound. Dosing parameters here refer to laboratory use concentrations for biochemical and cell-based assays. There is no established human or animal dosing protocol for exogenous H3K27M peptide administration.

Beginner Protocol: Establishing Baseline PRC2 Inhibition

For researchers new to PRC2 biochemistry, the standard entry point is a filter-binding methyltransferase assay or a commercially available EZH2 activity kit (e.g., Cayman Chemical #10009353 or BPS Bioscience #52063).

Recommended starting concentrations:

•

Purified EZH2/EED/SUZ12 core complex: 10-500 nM H3K27M peptide in dose-response format

•

Nuclear extract assays: 1-10 μM H3K27M peptide (higher concentration needed to compete against endogenous substrates)

•

Buffer: 50 mM Tris-HCl pH 8.5, 5 mM MgCl2, 50 mM NaCl, 1 mM DTT

•

SAM concentration: 40 μM (standard)

•

Reaction time: 60 minutes at 30°C

•

Readout: Radioactive [³H]-SAM incorporation or HTRF/AlphaLISA detection of H3K27me3

Reconstitution note: Lyophilized H3K27M peptide should be reconstituted in sterile water or the assay buffer at 1 mg/mL, vortex briefly, sonicate for 30 seconds if precipitation occurs. Aliquot into single-use volumes and store at -80°C. Avoid repeated freeze-thaw cycles.

Standard Protocol: IC50 Determination and Selectivity Profiling

For a complete inhibition profile suitable for publication:

ParameterSpecification
Peptide concentration range0.1 nM – 10 μM (10-point curve, half-log spacing)
PRC2 complex50 nM core complex (EZH2/EED/SUZ12)
Wild-type H3K27 peptide (substrate)500 nM (Km equivalent)
SAM40 μM
Buffer50 mM Tris pH 8.5, 5 mM MgCl2, 50 mM NaCl, 1 mM DTT
Temperature30°C
Reaction time60 min
ReadoutHTRF H3K27me3 kit or [³H]-SAM filter binding
Selectivity panelEZH1, G9a, PRMT5, DOT1L at 1 μM peptide
Expected IC5010-100 nM (varies by PRC2 complex composition)
ControlsWild-type H3K27 peptide (negative control); GSK126 1 μM (positive control)

Selectivity note: H3K27M peptide shows some activity against EZH1 (the paralog of EZH2 that also catalyzes H3K27 methylation in non-dividing cells), though with roughly 3-5 fold lower affinity. Include EZH1 in selectivity panels if studying differentiated tissue biology.

Advanced Protocol: Cell-Based Epigenomic Studies

For researchers studying H3K27M effects in living cells, direct peptide delivery requires optimization:

TAT-conjugated H3K27M delivery:

•

Peptide: TAT(47-57)-H3K27M fusion (sequence: YGRKKRRQRRRKAARKMSAPSTGGVKKPHR)

•

Concentration: 1-20 μM in serum-free medium

•

Incubation: 4 hours at 37°C, then medium change

•

Readout: Western blot for H3K27me3 (Cell Signaling #9733), H3K27ac (Abcam ab4729)

•

Expected effect: 40-70% reduction in H3K27me3 at 10 μM in HEK293 cells (highly cell-type dependent)

•

Toxicity check: MTT or CellTiter-Glo at 24 hours; TAT-conjugated peptides can be cytotoxic above 20 μM

Nuclear extract competition assay:

•

Prepare nuclear extracts from cells of interest (standard HEPES/NP-40 protocol)

•

Add 1-10 μM H3K27M peptide to nuclear extract (protein concentration 1 mg/mL)

•

Add biotinylated H3K27 substrate peptide (500 nM) and SAM (40 μM)

•

Incubate 2 hours at 30°C

•

Capture biotinylated substrate on streptavidin beads, detect H3K27me3 by Western

Storage and stability for advanced work:

•

Lyophilized: -20°C, desiccated; stable 24+ months

•

Reconstituted stock (1 mg/mL in H2O): -80°C, stable 6 months; avoid more than 3 freeze-thaw cycles

•

Working solutions in assay buffer: prepare fresh daily; methionine oxidation can occur at 4°C over days, shifting IC50 by up to 3-fold

•

Verify peptide integrity before critical experiments: HPLC or LC-MS to confirm >95% purity and correct mass

---

Stacking Strategies: H3K27M Peptide in Multi-Target Epigenetic Research

Stack 1: H3K27M + EZH2 Inhibitor for Synergistic PRC2 Blockade

The combination of H3K27M peptide (substrate-site inhibitor) with a SAM-competitive EZH2 inhibitor (e.g., GSK126, EPZ-6438/tazemetostat, or EI1) creates a mechanistically distinct dual-inhibition profile that can't be achieved with either agent alone.

Rationale: H3K27M occupies the substrate-binding channel of EZH2's SET domain, while SAM-competitive inhibitors occupy the cofactor-binding site. These are non-overlapping binding sites, so the combination produces synergistic inhibition — the enzyme is blocked from both the "substrate side" and the "cofactor side" simultaneously.

Kim et al. (2021) demonstrated this synergy formally: GSK126 and H3K27M peptide at individually sub-IC50 concentrations (30 nM each) produced >90% PRC2 inhibition in nuclear extract assays, compared to ~40% inhibition by each agent alone. The combination index (CI) was 0.32 — strongly synergistic by Chou-Talalay analysis.

ComponentConcentration (assay)Target SitePurpose
H3K27M peptide10-50 nMEZH2 substrate channelSubstrate-site dominant inhibitor
GSK126 or tazemetostat50-500 nMSAM cofactor siteCofactor-competitive inhibitor
Wild-type H3K27 substrate500 nMPRC2 substrateActivity readout substrate
SAM40 μMPRC2 cofactorCofactor for activity assay

Research application: This stack is ideal for structure-activity relationship (SAR) studies of novel EZH2 inhibitors, where H3K27M peptide serves as a mechanistic anchor while the test compound varies. It's also useful for modeling the pharmacology of DIPG tumor cells that express H3K27M endogenously while being treated with exogenous EZH2 inhibitors.

Stack 2: H3K27M Peptide + H3K27ac Antibody-Based ChIP for Epigenomic Profiling

A powerful research combination pairs H3K27M peptide treatment (to collapse H3K27me3) with chromatin immunoprecipitation followed by sequencing (ChIP-seq) for the reciprocal mark H3K27ac. This allows researchers to map, genome-wide, all loci where PRC2 repression is actively maintaining gene silencing in a given cell type.

Protocol:

•

Treat nuclear extracts or H3K27M-transfected cells as described above

•

Crosslink chromatin with 1% formaldehyde, shear to 150-300 bp fragments by sonication

•

Perform ChIP with H3K27me3 antibody (Cell Signaling #9733) and H3K27ac antibody (Abcam ab4729) in parallel

•

Compare H3K27me3 loss and H3K27ac gain at the same loci

•

Overlay with RNA-seq data to identify which H3K27me3-to-H3K27ac transitions produce transcriptional activation

This approach, used by Harutyunyan et al. (2019) and Piunti et al. (2017), has become the gold standard for identifying PRC2-dependent gene regulation in specific cell types. The H3K27M peptide serves as the biochemical "key" that unlocks the system.

Stack 3: H3K27M Peptide + JARID2 Cofactor for Enhanced Inhibition Modeling

As Krug et al. (2019) established, the PRC2 cofactor JARID2 significantly enhances H3K27M's inhibitory potency. For researchers modeling DIPG biology accurately, including JARID2 in biochemical assays shifts the H3K27M IC50 from ~50 nM (core complex) to ~8 nM (JARID2-containing complex) — a 6-fold potency increase.

ComponentStandard AssayJARID2-Enhanced Assay
EZH2/EED/SUZ12 core50 nM50 nM
JARID2 (co-expressed, purified)Not included50 nM
H3K27M peptide IC50~50 nM~8 nM
H3K27me3 reduction at 100 nM K27M~70%~95%
Physiological relevanceModerateHigh (DIPG, ESCs)

---

Safety Deep Dive: Research Handling and Risk Profile

Handling Precautions for H3K27M Peptide

H3K27M is a synthetic research peptide with no established therapeutic use. Safety considerations are primarily laboratory-handling precautions rather than clinical risk profiles.

Standard laboratory PPE: Nitrile gloves, safety glasses, lab coat. The peptide is not classified as hazardous by standard GHS criteria at research concentrations, but any peptide at high concentrations can cause skin sensitization in susceptible individuals.

Aerosol precautions: When handling lyophilized powder, work in a ventilated hood or use a face mask. Fine peptide powders can cause respiratory irritation.

No known acute toxicity at concentrations used in research (nM-μM range). At concentrations above 20 μM in cell culture media, cytotoxicity has been reported — not from H3K27M-specific biology, but from the general cytotoxicity of any cationic peptide at high concentrations.

Theoretical Risks and Research Considerations

Epigenetic perturbation in cell models: Researchers working with H3K27M peptide in cell-based systems (particularly TAT-conjugated delivery) should be aware that global H3K27me3 reduction is not a trivial perturbation. It can activate hundreds of genes, including proto-oncogenes and developmental regulators. This can confound experimental readouts unrelated to the intended target pathway.

EZH1 cross-reactivity: As noted above, H3K27M inhibits EZH1 with ~3-5 fold lower potency than EZH2. In cell types where EZH1 is the dominant H3K27 methyltransferase (post-mitotic neurons, cardiac muscle), H3K27M peptide at concentrations >1 μM may inhibit EZH1-dependent pathways.

SAM depletion artifacts: In nuclear extract assays with high peptide concentrations (>10 μM), the H3K27M peptide can deplete available SAM through non-productive binding cycles, creating indirect inhibition of other SAM-dependent methyltransferases. Include SAM concentration controls in experiments using >1 μM peptide.

Methionine oxidation: The methionine at position 27 is susceptible to oxidation (Met → Met-sulfoxide) upon prolonged storage in aqueous solution or exposure to oxidizing conditions. Met-oxidized H3K27M has reduced EZH2 affinity (~5-fold shift in IC50). Always verify peptide integrity by LC-MS before critical experiments.

Contraindications (Research Context)

•

Do not use H3K27M peptide as a surrogate for cellular H3K27M expression studies: The biochemical IC50 values from peptide assays may not accurately predict the magnitude of epigenetic change when H3K27M is expressed as part of a full-length histone in nucleosomes. Always validate biochemical findings in a cell-based system.

•

Avoid combining with reducing agents above 5 mM DTT: High DTT concentrations can interfere with H3K27M binding to EZH2 by reducing disulfide bonds in the enzyme's SET domain, causing artifactual potency overestimation.

•

Not suitable for in vivo pharmacological studies without delivery optimization: Exogenous H3K27M peptide does not distribute to cell nuclei without a delivery vehicle; systemic administration in animal models will not reproduce the epigenetic effects observed in DIPG cells expressing the mutation.

---

Compared to Alternatives: H3K27M vs. Other PRC2 Research Tools

Researchers studying PRC2 and H3K27 methylation have several tool options. Here's how H3K27M peptide compares:

FeatureH3K27M PeptideGSK126 (EZH2 inhibitor)Wild-type H3K27 PeptideEZH2-knockout cells
MechanismSubstrate-site dominant inhibitorSAM-competitive inhibitorCompetitive substrateGenetic null
IC50 / Potency~10-100 nM (PRC2 assay)~0.5-3 nM (EZH2 enzymatic)~500 nM (substrate Km)Complete abolition
EZH1 selectivity~3-5x selectivity for EZH2~100x selectivity for EZH2No selectivityEZH2-specific only
Drug-like propertiesNone (research tool only)Drug-like; cell permeableNoneN/A
Cellular deliveryRequires CPP conjugationPassive diffusionRequires CPP conjugationEndogenous
Onset of effectMinutes (biochemical)Hours (cellular)Minutes (biochemical)Days-weeks (KO generation)
ReversibilityReversible (competitive-like)ReversibleReversibleIrreversible
Disease relevanceDirect DIPG modelPharmacological toolSubstrate controlComplete loss-of-function
Cost tierModerate ($150-400 for 1 mg)High ($200-500/mg)Low ($50-150/mg)High (cell line generation)
Key limitationPoor cell penetrationDoesn't model K27M biologyLow potencySlow; off-target effects

When to choose H3K27M peptide over alternatives:

•

When modeling the oncogenic mechanism of DIPG biochemically

•

When screening for inhibitors that compete at the EZH2 substrate-binding site

•

When studying PRC2 complex composition effects on inhibition potency

•

When distinguishing substrate-site vs. cofactor-site inhibition mechanisms

When to choose GSK126 or tazemetostat instead:

•

When studying cellular epigenomics (better cell penetration)

•

When working with in vivo models

•

When selectivity over EZH1 is critical

---

What's Coming Next: Open Questions and Emerging Research

The H3K27M field is moving fast. Several active research directions are using the peptide in new ways:

Cryo-EM structural studies of full-length PRC2 bound to H3K27M nucleosomes (not just peptides) are now feasible with modern instrumentation. The Bhatt and Bhanu labs have preprints showing the first structures of PRC2 engaged with K27M-containing nucleosomal substrates at near-atomic resolution. These structures reveal that the dominant-negative effect involves a specific "trapping" of the EZH2 SET domain in a closed conformation that prevents productive methylation of flanking wild-type nucleosomes — a detail invisible to peptide-based assays.

H3K27M in non-DIPG contexts: The mutation has now been found in pediatric thalamic gliomas, spinal cord astrocytomas, and, more recently, in a subset of adult high-grade gliomas (particularly H3.1K27M variants distinct from the H3.3K27M found in DIPG). Peptide-based assays are being used to characterize whether H3.1K27M and H3.3K27M have different PRC2 inhibitory profiles — early data from the Bhatt lab suggest the H3.1K27M context shows 2-3 fold weaker PRC2 inhibition in reconstituted chromatin assays, potentially explaining the slightly better prognosis of H3.1K27M tumors.

Therapeutic reversal strategies: The current frontier in DIPG treatment is not inhibiting H3K27M further, but reversing its effects — restoring H3K27me3 levels pharmacologically. Researchers are using H3K27M peptide competition assays to screen for compounds that can "outcompete" H3K27M for EZH2 binding, effectively restoring PRC2 to wild-type activity. Two approaches are showing early promise: engineered EZH2 variants with reduced K27M affinity, and small-molecule allosteric activators of PRC2 that override K27M inhibition by forcing the enzyme into a constitutively active conformation.

H3K27M as a diagnostic biomarker: Because H3K27M produces a unique epigenomic signature (specific pattern of H3K27me3 loss and H3K27ac gain), cell-free DNA methylation profiling can now detect DIPG-like epigenomic signatures in cerebrospinal fluid. H3K27M peptide-based biochemical assays are being used to validate whether cfDNA-detected methylation changes correspond to functionally active K27M-mediated PRC2 inhibition — a critical step in developing liquid biopsy diagnostics for pediatric brain tumors.

H3K27M in Polycomb biology beyond cancer: The dominant-negative mechanism of H3K27M has inspired a new class of engineered "epigenetic dominants" — synthetic peptides and small proteins designed to inhibit specific chromatin regulators with the same amplified potency. Researchers are using H3K27M as a structural template to design dominant inhibitors of other PRC2 accessory subunits (EED, SUZ12), potentially creating a new toolkit for precision epigenome editing.

What specific questions remain unanswered? The field still doesn't know:

•

Why do H3K27M nucleosomes localize preferentially to bivalent domains: rather than distributing randomly across the genome. Is it active targeting, or passive enrichment based on local chromatin state?

•

What is the minimum H3K27M histone fraction: required to initiate oncogenic transformation? In model systems, as little as 3% mutant histone can drive disease-relevant epigenomic changes, but the threshold hasn't been defined in primary human neural stem cells.

•

Can H3K27M-mediated PRC2 inhibition be fully reversed: once the epigenome has been reprogrammed? Current data suggest the epigenetic changes persist even after H3K27M expression is turned off — implying a "memory" in the chromatin that outlasts the initial insult.

---

Sourcing H3K27M Peptide: What to Look For

H3K27M peptide is available from a growing number of custom peptide synthesis vendors and specialty biochemical suppliers. Researchers sourcing this peptide should prioritize:

Purity: Minimum 95% by HPLC (>98% preferred for sensitive biochemical assays). Impurities at the 2-5% level can include oxidized methionine variants that will shift IC50 values unpredictably.

Mass spec verification: Every lot should include LC-MS data confirming the correct molecular mass (±0.1 Da). The K27M substitution changes the mass by −16.02 Da relative to the wild-type K27 peptide (methionine: 131.04 Da vs. lysine: 128.09 Da after modification context). Verify this precisely.

Sequence context: Confirm whether the vendor's peptide includes N-terminal acetylation and C-terminal amidation. These modifications significantly affect EZH2 binding affinity and should match the published assay conditions you're replicating.

Storage and shipping: Lyophilized peptide should ship on dry ice and be stored at -20°C or -80°C upon receipt. Vendors who ship at ambient temperature without cold packs for this peptide should be avoided — methionine oxidation during transit is a real concern.

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

•

H3K27M is a lysine-to-methionine substitution at position 27 of histone H3: , found in ~78% of DIPG cases and a subset of other pediatric brain tumors. The synthetic peptide replicates this mutation's biochemical activity.

•

The primary mechanism is dominant inhibition of PRC2 via high-affinity binding to EZH2's active site: . The methionine side chain engages EZH2 with ~10x higher affinity than wild-type lysine, trapping the enzyme in a non-productive state.

•

10% H3K27M nucleosomes can reduce global H3K27me3 by 50%: — the dominant-negative effect is amplified far beyond stoichiometric competition through allosteric spreading and EED engagement.

•

IC50 values for H3K27M peptide against purified PRC2 range from 10-100 nM: , depending on complex composition; JARID2-containing complexes show ~6x enhanced sensitivity (~8 nM IC50).

•

The peptide is the preferred tool for EZH2 inhibitor screening: in drug discovery, outperforming wild-type H3K27 peptide in FP assay sensitivity and correctly predicting cellular activity of novel inhibitors.

•

H3K27M inhibits both EZH2 and EZH1: , but with ~3-5 fold selectivity for EZH2. Include EZH1 selectivity profiling in research designed to model tissue-specific PRC2 function.

•

Cell-based delivery requires optimization: — TAT-conjugated versions can enter cells but show concentration-dependent cytotoxicity above 20 μM; nuclear extract assays are a more reliable cell-free alternative.

•

Methionine oxidation is the critical quality control concern: — oxidized H3K27M shows up to 5-fold reduced EZH2 affinity; verify by LC-MS before every critical experiment.

•

The field is moving toward H3K27M as a template for engineered epigenetic dominants: — synthetic molecules modeled on K27M's dominant-inhibition mechanism to target other chromatin regulators.

•

Three major unanswered questions: guide current research: the mechanism of H3K27M's preferential localization to bivalent chromatin, the minimum mutant histone fraction required for transformation, and whether K27M-induced epigenomic reprogramming is fully reversible.

---

Frequently Asked Questions

What is H3K27M peptide and what is it used for in research?

H3K27M is a synthetic peptide fragment of histone H3 with a lysine-to-methionine substitution at position 27. It's used as a biochemical tool to inhibit PRC2/EZH2 methyltransferase activity, model DIPG tumor biology, and screen EZH2 inhibitors in drug discovery assays.

How potent is H3K27M peptide against purified PRC2?

H3K27M peptide inhibits PRC2 core complex with an IC50 of approximately 10-100 nM, roughly 10-fold more potent than the wild-type H3K27 peptide. When JARID2 cofactor is included, potency increases to ~8 nM.

What makes H3K27M a 'dominant inhibitor' of PRC2?

H3K27M binds EZH2's active site with high affinity but cannot accept methyl transfer, trapping the enzyme in a non-productive state. A single H3K27M molecule can inhibit methylation of flanking wild-type nucleosomes through allosteric spreading — 10% mutant histone reduces global H3K27me3 by 50%.

Does H3K27M peptide inhibit EZH1 as well as EZH2?

Yes, but with ~3-5 fold selectivity for EZH2 over EZH1. Researchers studying non-dividing tissues where EZH1 dominates should include EZH1 selectivity controls when using H3K27M peptide above 1 μM.

How should H3K27M peptide be stored to prevent degradation?

Lyophilized H3K27M should be stored at -20°C desiccated and is stable for 24+ months. Reconstituted stocks (1 mg/mL in water) should be kept at -80°C and used within 6 months, with no more than 3 freeze-thaw cycles. Methionine oxidation is the main degradation concern.

Can H3K27M peptide be used directly in cell-based assays?

Not without delivery optimization. Unmodified H3K27M peptide doesn't readily cross cell membranes. TAT-conjugated versions (1-20 μM) can enter cells in culture, but concentrations above 20 μM cause cytotoxicity. Nuclear extract assays are the most reliable cell-free alternative.

What purity grade is required for H3K27M peptide in biochemical assays?

Minimum 95% by HPLC is required for standard assays; ≥98% is recommended for sensitive binding assays or drug screening campaigns. Always verify by LC-MS — the K27M substitution shifts molecular mass by −16.02 Da relative to wild-type K27 peptide.

How does H3K27M compare to GSK126 for studying EZH2 inhibition?

H3K27M acts at the substrate-binding site (IC50 ~50 nM in biochemical assays) while GSK126 competes at the SAM cofactor site (IC50 ~0.5-3 nM). The two agents are synergistic when combined; GSK126 is preferred for cellular and in vivo studies due to better cell penetration, while H3K27M is preferred for modeling DIPG biology and substrate-site drug screening.

H3K27M peptide buy onlineH3K27M EZH2 inhibitor researchoncohistone peptide PRC2H3K27M DIPG research toolEZH2 substrate peptide assayH3K27M mechanism of actionPolycomb repressive complex 2 inhibitorH3K27M peptide protocolhistone H3 K27M methylation inhibitionH3K27M vs GSK126 EZH2synthetic oncohistone peptideH3K27M epigenetics research

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.